Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Basilea Pharmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Strong Sales Growth for Cresemba and Zevtera Trigger Further Milestone Payments to Basilea
Details : AVIR has license in Canada for Cresemba (isavuconazole sulfate), approved for use in adults and pediatrics from 1 year up to 18 years for invasive aspergillosis and invasive mucormycosis.
Product Name : Cresemba
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 28, 2025
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Basilea Pharmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
